Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
Acutely destabilized heart failure is one of the most common diagnoses in the modern health care system. It has high hospital readmission rates and significant short-, medium-, and long-term mortality, likely due to misdiagnosis or failure to assess adequate treatment before discharge. Cardiac biomarkers such as B-type natriuretic peptide and its amino terminal cleavage equivalent N-terminal fragment have rapidly become one of the key tools in the diagnosis and guidance of heart failure therapy. In this article, we shall review the data on the current use of the natriuretic peptides for the diagnosis, prognosis, and management of heart failure in both the outpatient and inpatient settings.
Green
Sandy M
SM
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Green
Jamie A
JA
Januzzi
James L
JL
D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D045265:Natriuretic Peptides / Q000097:blood*; D010359:Patient Readmission / Q000706:statistics & numerical data; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis
D015415:Biomarkers; D045265:Natriuretic Peptides; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain